Akebia Therapeutics, Inc. (AKBA) Reaches $6.45 After 9.00% Down Move; Shorts at WOOD GROUP JOHN PLC ORDINARY SHARES (WDGJF) Raised By 1.33%

John Wood Group PLC (OTCMKTS:WDGJF) Logo

WOOD GROUP JOHN PLC ORDINARY SHARES (OTCMKTS:WDGJF) had an increase of 1.33% in short interest. WDGJF’s SI was 2.27 million shares in February as released by FINRA. Its up 1.33% from 2.24M shares previously. With 200 avg volume, 11356 days are for WOOD GROUP JOHN PLC ORDINARY SHARES (OTCMKTS:WDGJF)’s short sellers to cover WDGJF’s short positions. The stock decreased 0.96% or $0.06 during the last trading session, reaching $6.64. About 3,000 shares traded or 610.90% up from the average. John Wood Group PLC (OTCMKTS:WDGJF) has 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a huge mover today! The stock decreased 2.86% or $0.19 during the last trading session, reaching $6.45. About 767,168 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 42.65% since February 13, 2018 and is downtrending. It has underperformed by 42.65% the S&P500. Some Historical AKBA News: 09/05/2018 – Akebia Therapeutics 1Q Loss/Shr 48c; 12/03/2018 – AKEBIA SEES VADADUSTAT TOP-LINE PHASE 3 DATA NEXT YEAR; 15/05/2018 – Ecor1 Capital Buys New 2.5% Position in Akebia Therapeutics; 12/03/2018 – Akebia Therapeutics 4Q Net $12.3M; 12/03/2018 – AKEBIA THERAPEUTICS FILES MIXED SECURITIES SHELF; 03/04/2018 – Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4); 22/03/2018 – Akebia Therapeutics Announces Proposed Public Offering of Common Stk; 26/03/2018 – Akebia Therapeutics Presenting at Conference Tomorrow; 23/04/2018 – DJ Akebia Therapeutics Inc, Inst Holders, 1Q 2018 (AKBA); 22/03/2018 – AKEBIA – INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL DEVELOPMENT, OPTIMIZATION OF VADADUSTAT PROGRAMThe move comes after 6 months negative chart setup for the $753.93M company. It was reported on Feb, 13 by Barchart.com. We have $5.87 PT which if reached, will make NASDAQ:AKBA worth $67.85 million less.

John Wood Group PLC, together with its subsidiaries, provides engineering, procurement, construction, and maintenance services to the gas and oil, and power generation industries in the United Kingdom, the United States, and internationally. The company has market cap of $4.35 billion. The firm operates through three divisions: Asset Life Cycle Solutions West, Asset Life Cycle Solutions East, and Specialist Technical Solutions. It currently has negative earnings. It offers project and modification services, such as engineering, project management, repair orders, construction, commissioning, and fabrication services; activities and maintenance services; and industrial services, including access and containment, rope access, insulation, painting and protective coatings, positive pressure habitats, heat treatment, composite wrap, industrial cleaning, asbestos remediation, building construction and civil engineering, passive fire protection, and mechanical and piping support services, as well as electrical, control, and instrumentation services.

More important recent John Wood Group PLC (OTCMKTS:WDGJF) news were published by: Seekingalpha.com which released: “John Wood Group’s Diversified Business Offers Stability – Seeking Alpha” on December 24, 2018, also Seekingalpha.com published article titled: “Be Cautious Before Selecting Saipem – Seeking Alpha”, Seekingalpha.com published: “Petrofac Will Take Time To Readjust To New Energy Market Scenario – Seeking Alpha” on January 03, 2019. More interesting news about John Wood Group PLC (OTCMKTS:WDGJF) was released by: Seekingalpha.com and their article: “SBM Offshore Is Making Adjustments To Find Growth – Seeking Alpha” with publication date: December 27, 2018.

More notable recent Akebia Therapeutics, Inc. (NASDAQ:AKBA) news were published by: Nasdaq.com which released: “Akebia Therapeutics (AKBA) Upgraded to Buy: Here’s What You Should Know – Nasdaq” on January 30, 2019, also Seekingalpha.com with their article: “Akebia: Is This A Potential Winner? – Seeking Alpha” published on January 11, 2019, Seekingalpha.com published: “Akebia Therapeutics and Keryx Biopharmaceuticals complete merger – Seeking Alpha” on December 13, 2018. More interesting news about Akebia Therapeutics, Inc. (NASDAQ:AKBA) were released by: Seekingalpha.com and their article: “Keryx’s Long-Awaited Merger With Akebia Complete – Seeking Alpha” published on December 17, 2018 as well as Nasdaq.com‘s news article titled: “Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for – Nasdaq” with publication date: November 07, 2018.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $753.93 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Analysts await Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report earnings on March, 11. They expect $-0.80 earnings per share, down 420.00% or $1.05 from last year’s $0.25 per share. After $-0.46 actual earnings per share reported by Akebia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 73.91% negative EPS growth.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart